These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21882282)

  • 1. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
    Williams RD; Al-Saadi R; Natrajan R; Mackay A; Chagtai T; Little S; Hing SN; Fenwick K; Ashworth A; Grundy P; Anderson JR; Dome JS; Perlman EJ; Jones C; Pritchard-Jones K
    Genes Chromosomes Cancer; 2011 Dec; 50(12):982-95. PubMed ID: 21882282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors.
    Schaub R; Burger A; Bausch D; Niggli FK; Schäfer BW; Betts DR
    Cancer Genet Cytogenet; 2007 Jan; 172(1):61-5. PubMed ID: 17175381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
    Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
    Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
    Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
    PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.
    Natrajan R; Little SE; Sodha N; Reis-Filho JS; Mackay A; Fenwick K; Ashworth A; Perlman EJ; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
    J Pathol; 2007 Jan; 211(1):52-9. PubMed ID: 17103382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.
    Natrajan R; Williams RD; Hing SN; Mackay A; Reis-Filho JS; Fenwick K; Iravani M; Valgeirsson H; Grigoriadis A; Langford CF; Dovey O; Gregory SG; Weber BL; Ashworth A; Grundy PE; Pritchard-Jones K; Jones C
    J Pathol; 2006 Sep; 210(1):49-58. PubMed ID: 16823893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.
    Woods AD; Berlow NE; Ortiz MV; Dela Cruz F; Siddiquee A; Coutinho DF; Purohit R; Freier KET; Michalek JE; Lathara M; Matlock K; Srivivasa G; Royer-Pokora B; Veselska R; Kung AL; Keller C
    Pediatr Blood Cancer; 2022 Feb; 69(2):e29401. PubMed ID: 34693628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple mechanisms of MYCN dysregulation in Wilms tumour.
    Williams RD; Chagtai T; Alcaide-German M; Apps J; Wegert J; Popov S; Vujanic G; van Tinteren H; van den Heuvel-Eibrink MM; Kool M; de Kraker J; Gisselsson D; Graf N; Gessler M; Pritchard-Jones K
    Oncotarget; 2015 Mar; 6(9):7232-43. PubMed ID: 25749049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.
    Ooms AH; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Huff V; Dome JS; Chi YY; Tian J; Geller JI; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Walz AL; van den Heuvel-Eibrink MM; de Krijger RR; Ross N; Gastier-Foster JM; Perlman EJ
    Clin Cancer Res; 2016 Nov; 22(22):5582-5591. PubMed ID: 27702824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
    Barrow J; Adamowicz-Brice M; Cartmill M; MacArthur D; Lowe J; Robson K; Brundler MA; Walker DA; Coyle B; Grundy R
    Neuro Oncol; 2011 Feb; 13(2):212-22. PubMed ID: 21138945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome analyses of 16 cases of Wilms tumor: different pattern in unfavorable histology.
    Peres EM; Savasan S; Cushing B; Abella S; Mohamed AN
    Cancer Genet Cytogenet; 2004 Jan; 148(1):66-70. PubMed ID: 14697643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
    Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
    Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between Histological and Array Comparative Genomic Hybridization Characterizations of Wilms Tumor.
    Chiang MR; Kuo CW; Wang WC; Hou TC; Kuo CY; Lu MY; Lai YC
    Pathol Oncol Res; 2019 Jul; 25(3):1199-1206. PubMed ID: 30671724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Gradual Transition Toward Anaplasia in Wilms Tumor Through Tolerance to Genetic Damage.
    Uno K; Rastegar B; Jansson C; Durand G; Valind A; Chattopadhyay S; Bertolotti A; Ciceri S; Spreafico F; Collini P; Perotti D; Mengelbier LH; Gisselsson D
    Mod Pathol; 2024 Jan; 37(1):100382. PubMed ID: 37951357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays.
    Rassekh SR; Chan S; Harvard C; Dix D; Qiao Y; Rajcan-Separovic E
    Cancer Genet Cytogenet; 2008 Apr; 182(2):84-94. PubMed ID: 18406869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.
    Wittmann S; Zirn B; Alkassar M; Ambros P; Graf N; Gessler M
    Genes Chromosomes Cancer; 2007 Feb; 46(2):163-70. PubMed ID: 17099873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of wilms tumors using SNP mapping array-based comparative genomic hybridization.
    Hawthorn L; Cowell JK
    PLoS One; 2011 Apr; 6(4):e18941. PubMed ID: 21544195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletions of 16q in Wilms tumors localize to blastemal-anaplastic cells and are associated with reduced expression of the IRXB renal tubulogenesis gene cluster.
    Mengelbier LH; Karlsson J; Lindgren D; Øra I; Isaksson M; Frigyesi I; Frigyesi A; Bras J; Sandstedt B; Gisselsson D
    Am J Pathol; 2010 Nov; 177(5):2609-21. PubMed ID: 20847289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.